期刊文献+

IL-17F在口腔鳞状细胞癌患者血清中的表达及意义 被引量:1

Expression of Interleukin 17F in Serum of Oral Squamous Cell Carcinoma Patients and Its Clinic Significance
下载PDF
导出
摘要 目的:探讨 IL-17F(interleukin 17F)在口腔鳞状细胞癌(OSCC)患者血清中的表达及意义。方法收集33例健康对照者、25例经病理证实为白斑的患者和80例 OSCC患者的血清,用 ELISA方法检测 IL-17F的表达水平,分析其与临床病理参数的关系。结果 OSCC患者血清 IL-17F水平为65.1±7.2 pg/ml,显著低于健康对照者(202.2±31.5 pg/ml)和白斑患者(168.2±17.4 pg/ml),差异均具有统计学意义(t=6.16,6.22,P<0.05),OSCC患者血清中IL-17F水平与TNM分期明显相关(P<0.05)。受试者工作特征曲线(ROC曲线)显示血清中 IL-17 F能够很好地区分健康人和 OSCC患者(P<0.05),其最佳临界值为37.8 pg/ml。结论 OSCC患者血清中 IL-17F的表达降低,提示其可能与肿瘤发生、发展相关。 Objective This study focus on the serum expression of IL-17F (interleukin 17F)and its’clinical diagnostic value for normal,leukoplakia patient and Oral Squamous Cell Carcinoma (OSCC)serum specimens.Methods The concentration of IL-17F in the serum was assessed by ELISA in healthy donors (n=33),leukoplakia patients (n=25)and OSCC patients (n=80).Results IL-17F concentration was lower in OSCC patients than in healthy donors and leukoplakia patients (65.1 pg/ml vs 202.2 pg/ml or 168.2 pg/ml,t=6.16,6.22,P〈0.05).The expression of IL-17F was positively associated to TNM stage in OSCC (P〈0.05).The receiver operating characteristic (ROC)curve suggests that IL-17F in serum was a good diagnostic marker to discriminate healthy people from leukoplakia patients,the cutoff values was 37.8 pg/ml.Conclu-sion The expression of IL-17F in serum correlated to OSCC progression and could be a potential diagnostic biomarker for oral disease.
出处 《现代检验医学杂志》 CAS 2016年第6期77-78,81,共3页 Journal of Modern Laboratory Medicine
基金 江苏省临床医学科技专项(BL2013005) 江苏省卫生厅课题项目(H201441)
关键词 IL-17F 口腔鳞状细胞癌 血清 筛查指标 interleukin 17 F oral squamous cell carcinoma serum diagnosis
  • 相关文献

参考文献2

二级参考文献45

  • 1Brocklehurst PR, Baker SR, Speight PM. Oral cancer scree- ning: what have we learnt and what is there still to achieve[J]. Future Oncol, 2010, 6(2):299-304.
  • 2Williams HK. Molecular pathogenesis of oral squamous carcinoma[J]. Mol Pathol, 2000, 53(4): 165-172.
  • 3Kong YW, Ferland-McCollough D, Jackson T J, et al. micro- RNAs in cancer management[J]. Lancet Oncol, 2012, 13(6): e249-e258.
  • 4Lopez-Camarillo C, Marchat LA, Arechaga-Ocampo E, et al. MetastamiRs: non-coding microRNAs driving cancer invasion and metastasis[J]. Int J Mol Sci, 2012, 13(2):1347- 1379.
  • 5Heneghan HM, Miller N, Kerin MJ. MiRNAs as biomarkers and therapeutic targets in cancer[J]. Curr Opin Pharmacol, 2010, 10(5):543-550.
  • 6Visone R, Croce CM. MiRNAs and cancer[J]. Am J Pathol, 2009, 174(4):1131-1138.
  • 7Nagpal JK, Das BR. Oral cancer: reviewing the present understanding of its molecular mechanism and exploring the future directions for its effective management[J]. Oral Oncol, 2003, 39(3):213-221.
  • 8Reibel J. Prognosis of oral pre-malignant lesions: signifi- cance of clinical, histopathological, and molecular biological characteristics[J]. Crit Rev Oral Biol Med, 2003, 14(1):47- 62.
  • 9Bos CL, van Baarsen LG, Timmer TC, et al. Molecular sub- types of systemic sclerosis in association with anti-centromere antibodies and digital ulcers[J]. Genes lmmun, 2009, 10(3): 210-218.
  • 10Metzker ML. Sequencing technologies-the next generation [J]. Nat Rev Genet, 2010, 11(1):31-46.

共引文献20

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部